1. Executive Summary
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Contrast Media Market
4. Market Overview
4.1. Market Segmentation
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Contrast Media Market Analysis and Forecast, 2022-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. List of Types of Diagnostic Imaging Tests
5.3. COVID-19 Pandemic Impact on Industry
6. Contrast Media Market Analysis and Forecast, by Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Type, 2017–2031
6.3.1. Iodine-based Compounds
6.3.2. Barium Sulfate-based Compounds
6.3.3. Gadolinium-based Compounds
6.3.4. Microbubbles/Microspheres
6.4. Market Attractiveness, by Type
7. Contrast Media Market Analysis and Forecast, by Administration
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Administration, 2017–2031
7.3.1. Oral
7.3.2. Rectal
7.3.3. Intravenous/Intrarterial
7.3.4. Others
7.3.5. 7.4 Market Attractiveness, by Administration
8. Global Contrast Media Market Analysis and Forecast, by Imaging Modality
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Imaging Modality, 2017–2031
8.3.1. CT/X-Ray
8.3.2. Ultrasound
8.3.3. MRI
8.3.4. Others
8.4. Market Attractiveness, by Imaging Modality
9. Global Contrast Media Market Analysis and Forecast, by Application
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Application, 2017–2031
9.3.1. Oncology
9.3.2. Cardiology
9.3.3. Neurology
9.3.4. Others
9.4. 9.4 Market Attractiveness, by Application
10. Global Contrast Media Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2017–2031
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America Contrast Media Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type, 2017–2031
11.2.1. Iodine-based Compounds
11.2.2. Barium Sulfate-based Compounds
11.2.3. Gadolinium-based Compounds
11.2.4. Microbubbles/Microspheres
11.3. Market Attractiveness, by Type
11.4. Market Value Forecast, by Administration, 2017–2031
11.4.1. Oral
11.4.2. Rectal
11.4.3. Intravenous/Intrarterial
11.4.4. Others
11.5. Market Attractiveness, by Administration
11.6. Market Value Forecast, by Imaging Modality, 2017–2031
11.6.1. CT/X-Ray
11.6.2. Ultrasound
11.6.3. MRI
11.6.4. Others
11.7. Market Attractiveness, by Imaging Modality
11.8. Market Value Forecast, by Application, 2017–2031
11.8.1. Oncology
11.8.2. Cardiology
11.8.3. Neurology
11.8.4. Others
11.9. Market Attractiveness, by Application
11.10. Market Value Forecast, by Country, 2022–2031
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Type
11.11.2. By Administration
11.11.3. By Imaging Modality
11.11.4. Application
11.11.5. By Country
12. Europe Contrast Media Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type, 2017–2031
12.2.1. Iodine-based Compounds
12.2.2. Barium Sulfate-based Compounds
12.2.3. Gadolinium-based Compounds
12.2.4. Microbubbles/Microspheres
12.3. Market Attractiveness, by Type
12.4. Market Value Forecast, by Administration, 2017–2031
12.4.1. Oral
12.4.2. Rectal
12.4.3. Intravenous/Intrarterial
12.4.4. Others
12.5. Market Attractiveness, by Administration
12.6. Market Value Forecast, by Imaging Modality, 2017–2031
12.6.1. CT/X-Ray
12.6.2. Ultrasound
12.6.3. MRI
12.6.4. Others
12.7. Market Attractiveness, by Imaging Modality
12.8. Market Value Forecast, by Application, 2017–2031
12.8.1. Oncology
12.8.2. Cardiology
12.8.3. Neurology
12.8.4. Others
12.9. Market Attractiveness, by Application
12.10. Market Value Forecast, by Country/Sub-region, 2022–2031
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Type
12.11.2. By Administration
12.11.3. By Imaging Modality
12.11.4. By Application
12.11.5. By Country/Sub-region
13. Asia Pacific Contrast Media Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type, 2017–2031
13.2.1. Iodine-based Compounds
13.2.2. Barium Sulfate-based Compounds
13.2.3. Gadolinium-based Compounds
13.2.4. Microbubbles/Microspheres
13.3. Market Attractiveness, by Type
13.4. Market Value Forecast, by Administration, 2017–2031
13.4.1. Oral
13.4.2. Rectal
13.4.3. Intravenous/Intrarterial
13.4.4. Others
13.5. Market Attractiveness, by Administration
13.6. Market Value Forecast, by Imaging Modality, 2017–2031
13.6.1. CT/X-Ray
13.6.2. Ultrasound
13.6.3. MRI
13.6.4. Others
13.7. Market Attractiveness, by Imaging Modality
13.8. Market Value Forecast, by Application, 2017–2031
13.8.1. Oncology
13.8.2. Cardiology
13.8.3. Neurology
13.8.4. Others
13.9. Market Attractiveness, by Application
13.10. Market Value Forecast, by Country/Sub-region, 2017–2031
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Type
13.11.2. By Administration
13.11.3. By Imaging Modality
13.11.4. By Application
13.11.5. By Country/Sub-region
14. Latin America Contrast Media Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Type, 2017–2031
14.2.1. Iodine-based Compounds
14.2.2. Barium Sulfate-based Compounds
14.2.3. Gadolinium-based Compounds
14.2.4. Microbubbles/Microspheres
14.3. Market Attractiveness, by Type
14.4. Market Value Forecast, by Administration, 2017–2031
14.4.1. Oral
14.4.2. Rectal
14.4.3. Intravenous/Intrarterial
14.4.4. Others
14.5. Market Attractiveness, by Administration
14.6. Market Value Forecast, by Imaging Modality, 2017–2031
14.6.1. CT/X-Ray
14.6.2. Ultrasound
14.6.3. MRI
14.6.4. Others
14.7. Market Attractiveness, by Imaging Modality
14.8. Market Value Forecast, by Application, 2017–2031
14.8.1. Oncology
14.8.2. Cardiology
14.8.3. Neurology
14.8.4. Others
14.9. Market Attractiveness, by Application
14.10. Market Value Forecast, by Country/Sub-region, 2017–2031
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Type
14.11.2. By Administration
14.11.3. By Imaging Modality
14.11.4. By Application
14.11.5. By Country/Sub-region
15. Middle East & Africa Contrast Media Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Type, 2017–2031
15.2.1. Iodine-based Compounds
15.2.2. Barium Sulfate-based Compounds
15.2.3. Gadolinium-based Compounds
15.2.4. Microbubbles/Microspheres
15.3. Market Attractiveness, by Type
15.4. Market Value Forecast, by Administration, 2017–2031
15.4.1. Oral
15.4.2. Rectal
15.4.3. Intravenous/Intrarterial
15.4.4. Others
15.5. Market Attractiveness, by Administration
15.6. Market Value Forecast, by Imaging Modality, 2017–2031
15.6.1. CT/X-Ray
15.6.2. Ultrasound
15.6.3. MRI
15.6.4. Others
15.7. Market Attractiveness, by Imaging Modality
15.8. Market Value Forecast, by Application, 2017–2031
15.8.1. Oncology
15.8.2. Cardiology
15.8.3. Neurology
15.8.4. Others
15.9. Market Attractiveness, by Application
15.10. Market Value Forecast, by Country/Sub-region, 2017–2031
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Type
15.11.2. By Administration
15.11.3. By Imaging Modality
15.11.4. By Application
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2022)
16.3. Company Profiles
16.3.1. GE Healthcare
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Type Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Bayer AG
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Type Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Bracco Diagnostic, Inc.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Type Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Guerbet Group
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Type Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Lantheus Medical Imaging, Inc.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Type Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. nanoPET Pharma GmbH
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Type Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Subhra Pharma Pvt. Ltd.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Type Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Spago Nanomedical AB
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Type Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
